Overall Score

Threat Of New Entrants

High regulatory and clinical barriers in medical devices make direct entry difficult.

However, NVRO’s weak profitability and negative cash flow reduce the strength of scale-based defenses.

Bargaining Power Of Suppliers

Supplier leverage appears moderate because NVRO maintains a healthy current ratio and cash position.

No fresh evidence suggests a major change in component or manufacturing dependency.

Bargaining Power Of Buyers

Hospitals and clinicians can exert pricing pressure, but NVRO’s specialized products limit easy substitution.

Negative margins and low operating cash flow suggest customers still have meaningful negotiating power.

Threat Of Substitutes

Alternative therapies and competing device platforms remain a meaningful substitute risk.

No new product or clinical data materially changes the substitution backdrop this month.

Industry Rivalry

Rivalry is elevated in medical devices, but NVRO’s low valuation suggests the market already discounts competitive pressure.

Persistent losses and weak cash generation indicate competition remains intense, though no new news worsened the picture this month.